Currently Viewing:
American Society of Hematology
Currently Reading
Ibrutinib More Effective Than Stem-Cell Transplant in Patients With Form of Chronic Leukemia
December 07, 2017
Significant Economic Burden Associated With Various AML Treatment Episodes
December 08, 2017
The Effects of Myeloproliferative Neoplasm Symptoms on Quality of Life
December 08, 2017
Using Time Spent at Home to Measure End-of-Life Care Quality
December 09, 2017
Treatment-Free Remission and Preventing Cardiotoxicity: The Future of CML Care
December 10, 2017
Single-Agent Ibrutinib Promising in MCL and CLL, Improves Patient Well-Being
December 10, 2017
Dr Kerry Rogers: Ibrutinib's Impact on Vaccine Response
December 10, 2017
Dr Derek Raghavan Outlines Challenges to Implementing Evidence-Based Guidelines
December 10, 2017
Balancing Hospice Utilization With the Need for Transfusion in Leukemia
December 11, 2017
CTL019 More Cost Effective in Pediatric Patients With Acute Lymphoblastic Lymphoma
December 11, 2017
Clonal Expansion and Aging Fuel the Development of Neoplasms, Say Experts at ASH
December 11, 2017
Dr Nina Shah on the Benefits of Outpatient HSCT When Possible
December 11, 2017
Dr Thomas LeBlanc: Patients With Blood Cancers Less Likely to Use Hospice Care
December 11, 2017
CAR T Progress: Global Submissions for Kymriah, 42% Ongoing Response With Yescarta in ZUMA-1 Patients
December 11, 2017
Dr Joshua Richter Discusses Patient Financial Burden of New Treatments and Cures
December 12, 2017
Dr Julie Wolfson Highlights Different Outcomes in AYAs With ALL Compared With Children
December 12, 2017
New Treatment Paradigm Supersedes ABVD in Advanced Hodgkin Lymphoma: The ECHELON-1 Study
December 12, 2017
Dr Stephen Schuster Outlines CAR T Results Seen in Leukemia, Lymphoma, and Myeloma
December 12, 2017
Diagnosing Non-Chemotherapy Drug-Induced Neutropenia
December 16, 2017
Care Utilization Patterns in Sickle Cell Disease: Managing Pain and Care Transitions in AYAs
December 18, 2017
New Drug Approvals in Leukemia and Lymphoma Presented at ASH 2017
December 18, 2017
Dr Derek Raghavan: Ensuring Guidelines Are Implemented and Followed
December 22, 2017
Diagnosing Congenital Neutropenia
December 23, 2017
Dr Shannon Maude Discusses Side Effects of CAR T Therapies
December 25, 2017

Dr Derek Raghavan: Evidence-Based Guidelines Will Improve Cancer Outcomes, Reduce Costs

The purpose of evidence-based guidelines is to reduce the level of variation, improve outcomes, and reduce costs, said Derek Raghavan, MD, PhD, FACP, FRACP, president, Carolinas HealthCare System's Levine Cancer Institute.

The purpose of evidence-based guidelines is to reduce the level of variation, improve outcomes, and reduce costs, said Derek Raghavan, MD, PhD, FACP, FRACP, president, Carolinas HealthCare System's Levine Cancer Institute.


With studies finding large variation and price differences in how care is delivered, what is the importance of putting in place evidence-based guidelines and ensuring they are followed?

One of the really important things about having evidence-based guidelines is, it’s stops the unnecessary variation. It basically gives what I have to describe as a “cookbook” approach to treatment. It’s predicated on level 1 evidence, which means randomized clinical trials, very carefully structured patient populations, so the stringency of assessment, the level of attention to detail of what population of patients with a set of drugs will get what results. That will reduce the level of variation that we have, and it becomes very important if you’re trying to get your arms around the cost of treatment.

If every physician wants to use every new drug, they’re almost always very expensive, you’ll have wide levels of variation of outcome, side effects, and cost. Increasingly, we move to the value proposition: what is the outcome for the unit cost? So, developing guidelines, that are predicated on expert opinions—so, you have a bunch of experts getting together and agreeing that their guidelines will be based on level 1 evidence from randomized trials or very well-structured trials. What’s happened in the past is, patterns of practice are sometimes from a bunch of good ol’ boys who get together and say, “I do this, what do you do? Oh, you do the same thing. Well, let’s say that’s the way to do it.” Now, we’re actually looking at the domain of evidence that’s out there, that’s published, that’s been peer-reviewed, and that’s true, and we then take into account the level of genetic variation, the level of population variation.

The Lancet Oncology commission recently published a statement that I think was terribly important: If every patient with cancer in the United States was able to have the results achieved by a college-educated white male, the death rate by cancer would drop by 25%. That’s a tremendously important statement. What it says is that in United States—and this actually isn’t restricted just to the United States—the people who have educated and resources get better results than the people who don’t. If you look in the field of disparities of care there are some less-educated African Americans and Hispanics, there are people that don’t speak the language from other groups, the elderly, the isolated poor, poverty itself will impede the ability to get great results. We’ve published data to show that patients on Medicaid and Medicare have worse results than people with private insurance.

By developing guidelines that take into account the variation of the populations that we’re treating, we should be able to improve the cancer treatment results in terms of cure rates and length of remissions, reduce the side effects, and, importantly, bring down the costs. If the medical profession doesn’t do this and doesn’t take leadership, then government functionaries will do it, and it will be predicated on misunderstanding of very complex data. So, we have to get this right and we have to do it as a profession.

Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
Welcome the the new and improved, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up

Sign In

Not a member? Sign up now!